Gossamer Bio, Inc. (GOSS)

Gossamer Bio's stock has experienced significant events and volatility over the past six months. In August 2025, the company announced its second-quarter financial results, reporting a net loss of $38.3 million, but the stock surged 74.19%. In September 2025, UBS upgraded the stock rating to Buy, increasing the price target to $9.00. In November 2025, the company announced its third-quarter financial results, reporting a loss of $48.2 million, and H.C. Wainwright reiterated a Buy rating with a $10.00 price target. In December 2025, Piper Sandler reiterated a Buy rating, setting a $15.00 price target, and Gossamer Bio confirmed the completion of enrollment in its Phase 3 PROSERA study for PAH. In January 2026, the stock gained 5.56% on January 13, 2026, though it had fallen by 17.13% in the preceding 10 days. The stock price increased by 160.78% over the past year as of January 2026.

Gossamer Bio, Inc. does not experience traditional demand seasonality for its products or services. The demand for its offerings is linked to the successful progression of its clinical trials, regulatory approvals, and eventual commercialization of its drug candidates, and its revenue and operational activities are not subject to seasonal fluctuations.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative therapeutic products within the Healthcare sector, specifically Biotechnology: Pharmaceutical Preparations. The company focuses on immunology, inflammation, and oncology, with an emphasis on addressing unmet medical needs in specific patient populations. Their leading drug, seralutinib, is in late-stage clinical trials for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Gossamer Bio's corporate and R&D presence is in San Diego, California, with a European office in Dublin, Ireland. Its global presence is primarily through clinical trials across North America, Europe, and other regions, collaborating with CROs, research institutions, and investigators worldwide.

Gossamer Bio's brand reputation is driven by the progress of seralutinib and positive analyst sentiment. The company has received a consensus rating of Strong Buy or Moderate Buy from analysts, who have highlighted the potential of seralutinib, particularly for its PAH trial, and have issued optimistic price targets. Presentations at investor conferences and the announcement of positive clinical and preclinical data have also contributed to a positive perception.

Gossamer Bio, Inc. has significant institutional ownership, with approximately 77.81% to 81.3% of its stock held by institutions, and insiders own about 15.24%. Major institutional owners include NEA Management Company, LLC, Octagon Capital Advisors LP, BlackRock, Inc., Vanguard Group Inc, Arch Venture Corp, FBIOX - Biotechnology Portfolio, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Samsara BioCapital, LLC, Palo Alto Investors LP, and Siren, L.L.C. Omega Fund V LP is the largest individual shareholder, owning 13.51 million shares, representing 5.84% of the company.